Develops innovative therapies and vaccines for cancer and infectious diseases, focusing on novel approaches and technologies.
Anixa Biosciences, Inc. is a dynamic biotechnology company dedicated to advancing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. The company's innovative therapeutic programs include pioneering a chimeric endocrine receptor T-cell therapy, a cutting-edge application of chimeric antigen receptor T-cell (CAR-T) technology aimed at treating ovarian cancer. Additionally, Anixa Biosciences is actively developing anti-viral drug candidates designed to combat COVID-19 by targeting specific protein functions of the virus.
On the vaccine front, Anixa Biosciences is engaged in developing a vaccine against triple negative breast cancer and a preventative vaccine for ovarian cancer. These initiatives highlight the company's commitment to leveraging immunotherapy approaches in the fight against cancer. Founded in 1982 as ITUS Corporation and rebranded in October 2018, Anixa Biosciences is headquartered in San Jose, California, and continues to drive innovation in biotechnology with a focus on transformative treatments for serious medical conditions.
With a robust portfolio of therapeutic and vaccine candidates in development, Anixa Biosciences aims to make significant strides in improving patient outcomes and advancing the forefront of medical science. By harnessing its expertise in molecular biology and immunotherapy, the company is poised to deliver novel solutions that address some of the most challenging diseases facing global healthcare today.